Glaukos Corporation (GKOS) — Analysis Summary
Glaukos Corporation (GKOS) has a market cap of $8.97B with year-over-year revenue growth of +32.3%. Net margin stands at -37.0%. The stock trades at a P/E ratio of -47.4.
Key Takeaways
- Revenue changed +32.3% year-over-year
- Net margin of -37.0%
- P/E ratio of -47.4
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, GKOS posted revenue growth of +32.3% and trades at a P/E of -47.4.
Glaukos Corporation (GKOS)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -43.2x — earnings do not cover interest payments
Operating margin at -36.1% — material operating losses
Net margin at -34.3% — significant losses
The latest filing shows negative free cash flow.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
1,094
Headquarters
ALISO VIEJO, CA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.